Physician profile
Michael J Payette
NPI 1952575573
$3,188,159.53
in general payments reported to CMS, 2019-2025
45 companies · $851K in 2025
The $851K reported for 2025 was more than what 99% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $142K · 2020: $91K · 2021: $164K · 2022: $460K · 2023: $631K · 2024: $848K · 2025: $851K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1.7M · Consulting Fee: $273K · Travel and Lodging: $265K · Food and Beverage: $58K · Honoraria: $17K · Education: $261.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,716,685.27 |
| Consulting Fee | $273,388.75 |
| Travel and Lodging | $265,335.80 |
| Food and Beverage | $58,419.16 |
| Honoraria | $16,830.87 |
| Education | $260.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $748,045.51 | 2019-2025 | |
| Genzyme Corporation | $307,896.75 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $306,812.13 | 2019-2025 | Dupixent, Libtayo |
| Incyte Corporation | $271,850.78 | 2021-2025 | Opzelura, Opzelura |
| E.R. Squibb & Sons, L.L.C. | $265,971.80 | 2022-2025 | Sotyktu |
| Janssen Biotech, INC. | $265,801.10 | 2019-2025 | Tremfya |
| Ucb, INC. | $253,995.23 | 2019-2025 | Bimzelx, Cimzia |
| Lilly USA, LLC | $151,843.90 | 2019-2025 | Ebglyss, Olumiant, Taltz |
| Arcutis Biotherapeutics, INC. | $126,259.95 | 2023-2025 | Zoryve |
| Janssen Scientific Affairs, LLC | $103,779.12 | 2019-2024 | Tremfya |
| Pfizer INC. | $78,372.71 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $59,246.06 | 2019-2025 | Cosentyx |
| Galderma Laboratories, L.P. | $58,083.69 | 2019-2025 | Nemluvio, Aklief |
| Amgen INC. | $48,456.09 | 2019-2025 | Otezla, Otezla |
| Sun Pharmaceutical Industries INC. | $43,831.38 | 2019-2025 | Ilumya |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Payette listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.